PHOTOCURE ASA
COMPANY PRESENTATION

20 September 2019

Erik Dahl, CFO

PHOTOCURE®

THE
BLADDER CANCER
COMPANY™

DISCLAIMER

By reading this company presentation (the “Presentation”), or attending any meeting or oral presentation held in relation thereto, you (the “Recipient”) agree to be bound by the following terms, conditions and limitations.

The Presentation has been produced by Photocure (the “Company”) for information purposes only and does not in itself constitute, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction. The distribution of this Presentation may be restricted by law in certain jurisdictions, and the Recipient should inform itself about, and observe, any such restriction. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction.

The Recipient acknowledge that it will be solely responsible for its own assessment of the Company, the market and the market position of the Company and that it will conduct its own analysis and be solely responsible for forming its own view of the potential future performance of the Company’s business. The Company shall not have any liability whatsoever (in negligence or otherwise) arising directly or indirectly from the use of this Presentation or its contents, including but not limited to any liability for errors, inaccuracies, omissions or misleading statements in this Presentation, or violation of distribution restrictions.

An investment in the Company involves significant risk, and several factors could adversely affect the business, legal or financial position of the Company or the value of its securities. For a description of relevant risk factors we refer to the Company’s annual report for 2018. Should one or more of these or other risks and uncertainties materialize, actual results may vary significantly from those described in this Presentation. An investment in the Company is suitable only for investors who understand the risk factors associated with this type of investment and who can afford a loss of all or part of their investment.

This Presentation contains certain forward-looking statements relating to inter alia the business, financial performance and results of the Company and the industry in which it operates. Any forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts and are subject to risks, uncertainties and other factors that may cause actual results and events to be materially different from those expected or implied by the forward-looking statements. The Company cannot provide any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of opinions expressed in this Presentation or the actual occurrence of forecasted developments.

This Presentation speaks as at the date set out on herein. Neither the delivery of this Presentation nor any further discussions of the Company shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The Company does not assume any obligation to update or revise the Presentation or disclose any changes or revisions to the information contained in the Presentation (including in relation to forward-looking statements).

This Presentation is subject to Norwegian law, and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of Norwegian courts.

PHOTOCURE BEFORE AND NOW:

Global Leader in Photodynamic Therapy (PDT)

As of 1997

New strategic focus:

The Bladder Cancer Company

2018

Continue success of Hexvix®/Cysview®

Expand portfolio of bladder cancer assets

2020 + beyond

PHOTOCURE AT A GLANCE



75

employees
of which **45** in US

Norwegian **commercial-stage pharmaceutical company** focused on bladder cancer

Own **commercial operations** in Nordics and USA. **Partners** in Europe, Canada, Australia and New Zealand

---

UNIQUE Photocure Technology® Platform
Used for diagnosis and treatment

PHOTOCURE AT A GLANCE

Oslo (HQ)

Princeton (NJ)

~$140M

Market cap

150K

Avg Daily Vol LTM

OSLO STOCK EXCHANGE:

IPO
May, 2000

Core drug-device product on market

HEXVIX® Hexaminolevulinate 85mg

CYSVIEW® Hexaminolevulinate HCl

Bladder cancer detection & management

Accelerating revenue growth

+20% total revenue growth in 2018

$ 35M global in-market sales*

Over **500 000** patients treated with Hexvix/Cysview worldwide

* Total In Market Sales including US, Nordic and Partners

PHOTOCURE® THE BLADDER CANCER COMPANY™

PHOTOCURE STRATEGY — FOUR STEPS

TO BECOME A TRANSFORMATIVE, MULTI-PRODUCT, BLADDER CANCER COMPANY



ACCELERATE

Grow Cysview®/Hexvix®

EXPAND

Surveillance market
New geographies

ACQUIRE

Expand portfolio of bladder cancer/bladder assets

TRANSFORM

Build pipeline - partner/acquisitions

Hexvix® /Cysview® Positioning

NON-MUSCLE INVASIVE BLADDER CANCER

IS ONE OF THE MOST COMMON CANCERS WITH SIGNIFICANT RECURRENCE RATE AND HIGH DISEASE BURDEN



Tumor as seen through a cystoscope

~650K
surgical procedures annually in USA and EU

~2.2M
surveillance cystoscopies annually in USA and EU

More than **60%**
disease recurrence at 1 year[1]

10% – 30%
disease progression

$3.7 Billion
in direct medical costs/year[2]

Picture: Mayo Clinic; Researchgate.net

1. Sylvester RJ et al. Eur Urol 2006; 49: 466-467
2. Direct medical costs in USA in 2001: The health economics of bladder cancer: a comprehensive review of the published literature. Botteman MF et al. Pharmacoeconomics 2003;21 (8), 1315-1330

HEXVIX®/CYSVIEW® ADDRESSES THE NEED FOR **IMPROVED DETECTION AND MANAGEMENT OF BLADDER CANCER**



Diagram based on report by hcrnetwork.com

TURBT: trans-urethral resection of bladder tumors

BLUE LIGHT CYSTOSCOPY WITH HEXVIX®/CYSVIEW®?

A TRANSFORMATIVE SOLUTION TO **IMPROVE THE LIVES OF PATIENTS** WITH BLADDER CANCER



WLC BLC™ with Hexvix/Cysview

Key benefits

- Improved Patient outcomes (diagnostic accuracy + surgical results)
- Significant reduction of disease recurrence
- Reduction in disease progression
- Improved cost-effective health outcomes

Additional tumors found in **1** out of **4** patients[1]

Additional papillary tumors in **25%** of patients[1]

35% of patients with CIS were only found with Cysview® [2]

1. Burger et al. Eur. Urol. 2013 WLC: White Light Cystoscopy; BLC: Blue Light Cystoscopy + Cysview®
2. Daneshmand S et al. Efficacy and Safety of Blue Light Flexible Cystoscopy With Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multi-Center Study JofU online. 2017.

BLUE LIGHT CYSTOSCOPY WITH HEXVIX®/CYSVIEW®

Key feature

Better visual contrast between benign and malignant cells

Blue Light Cystoscopy (BLC™) with Hexvix/Cysview is a **drug and device combination** for better detection and management of NMIBC.

Hexvix/Cysview is a pharmaceutical product that is taken up selectively by cancer cells in the bladder making them glow bright pink when illuminated with Blue Light.

Hexvix/Cysview is used with a blue light enabled cystoscope, from Karl Storz, Wolf or Olympus.

Positioned for growth

ACCELERATED MOMENTUM
6 CONSECUTIVE QUARTERS OF RECORD REVENUES IN US



ACCELERATED MOMENTUM
INSTALLED BASE OF CYSTOSCOPES IN THE US



SUPPORTIVE ENVIRONMENT & INCREASING AWARENESS

FOR BECOMING THE **STANDARD OF CARE** FOR THE DETECTION AND MANAGEMENT OF BLADDER CANCER

- **Inclusion in Bladder Cancer treatment guidelines**
  BLC™ with Hexvix® /Cysview® is strongly recommended by US, European and national guidelines as well as expert panels.

American Urological Association | SUO Society of Urologic Oncology, Inc. | eau European Association of Urology | NICE National Institute for Health and Care Excellence

- **High adoption rate in top Cancer centers**
  Established in >170 key US cancer hospitals and leading institutions. **25%** to **70%** penetration rate in the Nordics
- **Patient preference**
  growing awareness and active preference as shown in recent BCAN survey
- **Favorable and Permanent US Reimbursement 2019**
  for BLC™ with Cysview® on all settings of care
- **Activating awareness**
  in the healthcare community through major congress presence and media campaign
- **Partnering with prominent Patient Associations**
  especially BCAN in the US and the new World Bladder Cancer Patient Coalition

PHOTOCURE® THE BLADDER CANCER COMPANY™

HEXVIX®/CYSVIEW® – KEY ENABLERS IN PLACE AND READY FOR GROWTH



Key success factors

Approval – surgical & surveillance

Acceptance – major & local guidelines

Access – Permanent and favorable reimbursement

"Activated" Awareness – Patient demand via advocacy groups and media

Accelerate – Commercial investment to optimize the opportunity

Cevira® License Agreement

CEVIRA®: LICENSE AGREEMENT WITH ASIERIS

ASIERIS MEDITECH CO., Ltd.

- Asieris is a subsidiary of the China-based Jiangsu Yahong Meditech Co., Ltd., a specialty pharma company fully committed to research, development and commercialization of innovative new medical treatments through their own IP and in-licensing efforts.
- CEO of Asieris: Kevin Pan

- Its leading drug candidate, an oral drug for treating non-muscle invasive bladder cancer, is in a registrational clinical trial in China and Phase Ib trial in the US.
- Asieris has built strong development capabilities in the genitourinary diseases (GU) area in China and is rapidly expanding its global capability.

CEVIRA® – CERVICAL CANCER



- Potential to fill high unmet need for non-surgical treatment of HPV/CIN populations
- Breakthrough, single use, integrated drug-device technology

- Potential to treat high grade cervical dysplasia independent of HPV genotype
- Easy and convenient for provider and patient

CEVIRA®: TERMS OF LICENSE AGREEMENT WITH ASIERIS

TERMS OF THE LICENSING AGREEMENT*

- Under the License Agreement, Photocure will receive a total signing fee of USD 5 million within 6 months after signing.
- Approval of the initial indication will result in USD 18 million in China and USD 36 million in US/EU
- A second indication in China, the US and the EU would result in payments of up to USD 14 million.
- Sales royalties and milestones will apply in all markets.

* Payments for certain performance milestones related to pivotal trials are due at a certain time or when reaching the milestone.

Financials

SEGMENT PERFORMANCE SECOND QUARTER 2019

Amounts in NOK million	Q2 '19	Q2 '18	Change	YTD '19	YTD '18	Change
Commercial Franchise						
Nordic revenue	10.7	10.8	-1%	23.8	22.9	4%
US revenue	24.5	16.1	52%	45.6	28.8	59%
Partner revenue	16.9	15.6	8%	33.9	31.4	8%
Total Hexvix/Cysview	**52.1**	**42.4**	23%	**103.3**	**83.1**	24%
Other revenue	0.9	3.2		1.9	4.1	
Total revenue	**53.0**	**45.7**	16%	**105.2**	**87.2**	21%
Operating expenses	-46.9	-36.1	30%	-92.0	-73.4	25%
EBITDA recurring	**1.5**	**4.8**		**3.2**	**5.7**	
Development Portfolio						
Operating expenses	-4.1	-4.1	-1%	-7.3	-9.1	-20%
EBITDA recurring	**-4.1**	**-4.1**		**-7.3**	**-9.1**	
TOTAL						
EBITDA recurring	**-2.6**	**0.7**		**-4.1**	**-3.4**	

Commercial Franchise

- US: Strong revenue growth, Q2 41% and YTD 46% in USD
  - Installed base of rigid and flex BLC 188 at quarter end, increased 45% YOY
- Nordic: Q2 revenue at level with last year, YTD growth 4%, strong development in Sweden and Finland
- Partner: Q2 and YTD revenue growth 8%, driven by Germany, France (Ipsen) and Canada (BioSyent)
- Increased operating expenses, Q2 at 30% YOY, commercial investments in US

Development Portfolio

- Operating expenses Q2 and YTD include one-off costs related to agreement with Asieris

CONSOLIDATED INCOME STATEMENT SECOND QUARTER 2019

Amounts in NOK million	Q2 '19	Q2 '18	Change	YTD '19	YTD '18	Change
Hexvix/Cysview revenue	52.1	42.4	23%	103.3	83.1	24%
Other revenue	0.9	3.2	-72%	1.9	4.1	-54%
Total revenue	**53.0**	**45.7**	16%	**105.2**	**87.2**	21%
Gross profit	**48.5**	**40.9**	**18%**	**95.2**	**79.1**	**20%**
Operating expenses	-51.0	-40.2	27%	-99.3	-82.5	20%
EBITDA recurring	**-2.6**	**0.7**		**-4.1**	**-3.4**	
Depreciation & Amort.	-4.2	-3.3		-8.5	-6.5	
Restructuring expenses		-13.1			-13.1	
EBIT	**-6.8**	**-15.7**		**-12.6**	**23.0**	
Net financial items	0.1	0.1		-0.1	-0.1	
Earnings before tax	**-6.7**	**-15.6**		**-12.6**	**-23.1**	
Tax expenses	1.5	-1.4		2.6	3.1	
Net earnings	**-5.2**	**-17.0**		**-10.1**	**-20.0**	

- Operating expenses, increase driven by
  - Planned investments in US commercial operations (sales & marketing)
  - Business development expenses particularly related to Cevira (other operating expenses)
- Operating expenses, significant FX impact
  - Growth in constant currencies; Q2 20% and YTD 14%



PHOTOCURE® THE BLADDER CANCER COMPANY™

CASH FLOW
SECOND QUARTER 2019

Amounts in NOK million	Q2 ‘19	Q2 ‘18	YTD ’19	YTD ‘18
Operations cash flow	**-4.0**	**-11.5**	**-19.7**	**-30.0**
Earnings before tax	-6.7	-15.6	-12.6	-23.1
Working capital	0.6	0.0	-12.0	-11.0
Other	2.1	4.1	4.9	4.0
Investments cash flow	**0.1**	**-0.8**	**0.7**	**-0.9**
Development exp.	-	-0.2	-	-0.6
Other	0.1	-0.6	0.7	-0.3
Financing cash flow	**-0.9**	**-0.6**	**-1.1**	**-0.6**
Share capital	-	-	0.6	-
Other	-0.9	-0.6	-1.8	-0.6
Net change in cash	**-4.7**	**-12.8**	**-20.2**	**-31.4**
Ending cash balance	**86.7**	**97.9**	**86.7**	**97.9**

- Cash flow from operations Q2 NOK -4.0 million, improvement of NOK 7.5 million from Q2 last year. YTD improvement of NOK 10.3 million to NOK -19.7 million
  - 2018 cash flow impacted by restructuring at the end of Q2
- Cash flow from financing includes payment of lease liability totaling NOK 0.9 million in Q2 and NOK 1.8 million YTD
- Net change in cash improved NOK 8.1 million in Q2 and NOK 11.2 million YTD compared to last year
- Quarter end cash balance at NOK 86.7 million

BALANCE SHEET
30 JUNE 2019

Amounts in NOK million	30.06 2019	31.12 2018
Non current assets	82.4	77.8
Investments	18.6	24.6
Tax asset	55.0	52.4
Other	8.8	0.7
Inventory & receivables	51.9	46.6
Cash & equivalents	86.7	106.8
Total assets	**221.0**	**231.2**
Shareholders equity	166.7	176.3
Long term liabilities	11.3	2.5
Current liabilities	43.0	52.3
Total equity & liabilities	**221.0**	**231.2**
Equity ratio	*75%*	*76%*

- Non current assets
  - Investments of NOK 18.6 million in tangible and intangible assets is driven by investments in Cysview phase 3 project
  - Deferred tax asset of NOK 55.0 million
  - Other items includes impact from adoption of IFRS 16 (Leases) from 1 January 2019
- Inventory & receivables driven by revenue increase
- Long term liabilities include impact from adoption of IFRS 16 (Leases) from 1 January 2019
- No interest bearing debt
- Shareholder’s equity of NOK 166.7 million. Equity ratio of 75%

Summary and Outlook

PHOTOCURE STRATEGY — FOUR STEPS

TO BECOME A TRANSFORMATIVE, MULTI-PRODUCT, BLADDER CANCER COMPANY

TRANSFORM

Build pipeline -
partner/acquisitions

ACQUIRE

Expand portfolio of bladder
cancer/bladder assets

EXPAND

Surveillance market
New geographies

ACCELERATE

2020 revenue outlook of
20-25M$ in the US
Grow Cysview®/Hexvix®